Corrigendum
Corrigendum to “Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG oncology study (NRG-GY008)” [Gynecol. Oncol. Rep. 31 (2020) 100532]

https://doi.org/10.1016/j.gore.2020.100590
Under a Creative Commons license
open access

Cited by (0)

© 2020 The Author(s). Published by Elsevier Inc.